Ratings BioCardia, Inc.

Equities

BCDA

US09060U5074

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
0.3799 ^USD	+1.31%		+0.88%	-42.80%

01/05	BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	CI
30/04	Transcript : BioCardia, Inc. - Special Call

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BIOCARDIA, INC.	-42.80%	10.21M		-
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B		B+
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B		B+
ARGENX SE	+4.40%	22.94B		B
BIONTECH SE	-12.15%	22.34B		B+
GENMAB A/S	-4.36%	19.25B		A-
WUXI APPTEC CO., LTD.	-39.98%	17.08B		A-
BEIGENE, LTD.	-10.04%	16.96B		B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B		C+
VIKING THERAPEUTICS, INC.	+313.59%	8.49B	-	D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes